Nkarta, Inc. (NASDAQ:NKTX – Get Rating) CEO Paul J. Hastings sold 6,126 shares of the business’s stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $13.01, for a total value of $79,699.26. Following the completion of the sale, the chief executive officer now owns 274,335 shares in the company, valued at $3,569,098.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Nkarta Stock Performance
NKTX opened at $12.52 on Friday. The stock has a market cap of $609.22 million, a price-to-earnings ratio of -4.52 and a beta of 0.07. The stock’s 50 day moving average price is $14.58 and its 200-day moving average price is $13.36. Nkarta, Inc. has a one year low of $7.55 and a one year high of $31.45.
Nkarta (NASDAQ:NKTX – Get Rating) last released its earnings results on Thursday, August 11th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.11. As a group, analysts predict that Nkarta, Inc. will post -2.57 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
NKTX has been the topic of a number of research analyst reports. SVB Leerink initiated coverage on Nkarta in a research report on Monday, July 18th. They issued an “outperform” rating and a $30.00 target price on the stock. Needham & Company LLC assumed coverage on Nkarta in a research report on Thursday, July 28th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Nkarta in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nkarta currently has an average rating of “Buy” and an average price target of $39.63.
Nkarta Company Profile
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.